Market Overview

UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

Share:
Related NBIX
Mid-Day Market Update: Akamai Technologies Surges On Earnings Beat; KapStone Paper and Packaging Shares Drop
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
Notable earnings after Thursday's close (Seeking Alpha)

In a report published Wednesday, Morgan Stanley analyst David Friedman downgraded Neurocrine Biosciences (NASDAQ: NBIX) to EqualWeight from OverWeight, raising its price target to $16.00.

According to the report, the price target increase is based on a set of model changes including adding VMAT sales. The downgrade is due to the recent stock appreciation.

“While we expect clinical and commercial success for Elagolix in both endometriosis and uterine fibroids, we are changing our rating from OW to EW based on a seemingly more balanced risk-reward with the stock at current levels,” the report noted. “We have made a series of model changes, including adding '854 (VMAT) sales to our model in light of the recent, albeit somewhat modest benefit shown in the KINECT 2.”

NBIX closed Tuesday at $18.51 with shares trading up 89.69 percent.

Latest Ratings for NBIX

DateFirmActionFromTo
Feb 2016JP MorganMaintainsOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: David Friedman Morgan StanleyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters